BioWorld: The Daily Biopharmaceutical and Medical …
In the newest BioWorld Insider podcast, Victoria Lipinska, the America's lead for Quantum Innovation Centers at IBM Quantum, talks about the future of drug development using …
BioWorld: The Daily Biopharmaceutical News Source
Daily news and analysis of the global biotechnology and pharmaceutical industries. In-depth coverage of business, financing, regulation, science, innovation, drug approvals, clinical trials …
Coronavirus - Articles - BioWorld
2024年11月12日 · The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration.Note that we …
GI Dynamics enrolls first patient in pivotal Endobarrier trial
GI Dynamics Inc.’s U.S. IDE trial of Endobarrier, which is designed for patients diagnosed with type 2 diabetes and obesity, is now underway with the first patient enrollment at Michigan …
China - Articles - BioWorld
2024年11月6日 · University of Auckland senior research fellow Jeff Smaill first visited China in 2012 as part of a team of 15 scientists from the Maurice Wilkins Center, one of New Zealand’s …
| BioWorld
2024年10月17日 · Gene and cell therapies will drive innovation for the next 10 years, Claus Zieler, the chief commercial officer at Astellas Pharma Inc., said in this episode of the …
Nuala Moran - BioWorld
2024年10月3日 · The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of …
Today's news in brief | BioWorld
5 天之前 · BioWorld briefs for Nov. 19, 2024. Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat …
Novo Nordisk wins first FDA approval for long-acting …
2020年9月1日 · The first weekly therapy for adult growth hormone deficiency (GHD) has arrived in the U.S. with FDA approval for Novo Nordisk A/S' Sogroya (somapacitan). It’s the first of …
Lee Landenberger - BioWorld
The bad news keeps piling up for Sage Therapeutics Inc. Having absorbed other study stumbles in the past few months, the company now has halted development of dalzanemdor in treating …